Table 2.
Approved liposomal formulations for cancer treatment and their indications.
| Liposomal Formulation | Encapsulated Drug | Indication |
|---|---|---|
| DepoCyt™ | Cytarabine | Lymphomatous meningitis, intrathecal treatment |
| Vyxeos™ | Cytarabine + Daunorubicin | Newly-diagnosed therapy-related acute myeloid leukaemia in adults Acute myeloid leukaemia with myelodysplasia-related changes in adults |
| DaunoXome™ | Daunorubicin | Advanced AIDS-related Kaposi’s sarcoma (discontinued by the U S Food and Drug Administration in 2016) |
| Caelyx™ | Doxorubicin | Metastatic breast cancer where there is an increased cardiac risk associated with conventional doxorubicin Advanced ovarian carcinoma, in women who failed standard first-line platinum- and paclitaxel-based chemotherapy AIDS-related Kaposi’s sarcoma, in patients with low CD4 counts and extensive mucocutaneous or visceral disease, whose disease progressed despite therapy, or who are intolerant to prior systemic combination therapy comprising of at least two of the following agents: a vinca alkaloid, bleomycin, and doxorubicin (or another anthracycline) |
| Doxil™ | Doxorubicin | Ovarian cancer after failure of platinum-based chemotherapy AIDS-related Kaposi’s sarcoma after failure of prior combination chemotherapy, or intolerance to such therapy Multiple myeloma that did not previously receive bortezomib and received at least one prior therapy, in combination with bortezomib |
| Myocet™ | Doxorubicin | Metastatic breast cancer, first-line treatment in adult women, in combination with cyclophosphamide |
| Onivyde™ | Irinotecan | Metastatic adenocarcinoma of the pancreas after disease progression following gemcitabine-based therapy, in combination with 5-fluorouracil and leucovorin |
| Mepact™ | Mifamurtide | High-grade resectable non-metastatic osteosarcoma, after macroscopically complete surgical resection in children, adolescents, and young adults, in combination with post-operative multiagent chemotherapy |
| Marquibo™ | Vincristine | Philadelphia chromosome-negative acute lymphoblastic leukaemia, in adult patients in second or greater relapse, or whose disease has progressed following two or more anti-leukaemia therapies |
The information relative to the indications was obtained from the prescribing information of the respective liposomal formulations as of 2018.